Bullseye Asset Management LLC Has $2.67 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Bullseye Asset Management LLC lessened its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 161,860 shares of the medical research company’s stock after selling 1,932 shares during the period. Bullseye Asset Management LLC’s holdings in NeoGenomics were worth $2,667,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Franklin Resources Inc. grew its stake in shares of NeoGenomics by 2.0% during the 3rd quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company’s stock worth $28,225,000 after acquiring an additional 39,740 shares during the period. Versant Capital Management Inc increased its stake in shares of NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares in the last quarter. Nordea Investment Management AB raised its position in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock valued at $1,301,000 after purchasing an additional 2,125 shares during the period. Moody National Bank Trust Division lifted its stake in shares of NeoGenomics by 20.2% during the 4th quarter. Moody National Bank Trust Division now owns 73,226 shares of the medical research company’s stock valued at $1,207,000 after buying an additional 12,314 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in NeoGenomics by 16.7% in the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 56,000 shares of the medical research company’s stock worth $923,000 after buying an additional 8,000 shares during the period. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Stock Performance

NeoGenomics stock opened at $10.09 on Friday. The firm has a fifty day simple moving average of $9.84 and a two-hundred day simple moving average of $13.50. NeoGenomics, Inc. has a twelve month low of $8.05 and a twelve month high of $19.12. The company has a market capitalization of $1.30 billion, a PE ratio of -16.27 and a beta of 1.41. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The company had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Research analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Piper Sandler lowered their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC dropped their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Bank of America cut their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, The Goldman Sachs Group cut their price target on shares of NeoGenomics from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.30.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.